<i>BRAF</i> Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale

<i>BRAF</i> Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale

<i>BRAF</i> V600 mutations have been found in 1&#8722;2% of non-small-cell lung cancer (NSCLC) patients, with Food and Drug Administration (FDA) approved treatment of dabrafenib plus trametinib and progression free survival (PFS) of 10.9 months. However, 50&#8722;80% of <i>...

Full description

Bibliographic Details
Main Authors: Jillian Wilhelmina Paulina Bracht, Niki Karachaliou, Trever Bivona, Richard B. Lanman, Iris Faull, Rebecca J. Nagy, Ana Drozdowskyj, Jordi Berenguer, Manuel Fernandez-Bruno, Miguel Angel Molina-Vila, Rafael Rosell
Format: Article
Language:English
Published: MDPI AG 2019-09-01
Series:Cancers
Subjects:
BRAF
NSCLC
SHP2
PTPN11
MEK
MAPK
Online Access:https://www.mdpi.com/2072-6694/11/9/1381

Similar Items

Similar Items